Evidence map›Paper›PMID 34156605›Full record

ArticleMolecular biology reports2021

Apoptotic mechanisms of myricitrin isolated from Madhuca longifolia leaves in HL-60 leukemia cells.

Monaj Kumar Sarkar, Amrita Kar, Adithyan Jayaraman, Karthi Shanmugam, Vellingiri Vadivel, Santanu Kar Mahapatra

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Monaj Kumar SarkarChemical Biology Lab (ASK-II-409), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India.
Amrita KarMedicinal Chemistry and Immunology Lab (ASK-II-406), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India.
Adithyan JayaramanMedicinal Chemistry and Immunology Lab (ASK-II-406), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India.
Karthi ShanmugamDepartment of Bioinformatics, School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India.
Vellingiri VadivelChemical Biology Lab (ASK-II-409), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India. vadivel@carism.sastra.edu.ORCID http://orcid.org/0000-0002-2709-433X
Santanu Kar MahapatraMedicinal Chemistry and Immunology Lab (ASK-II-406), School of Chemical and Biotechnology (SCBT), SASTRA Deemed University, Thanjavur, India. santanu@scbt.sastra.edu.
SASTRA University · IN

Funding

National Medicinal Plants Board, Ministry of AYUSH, Government of India R&D/TN-03/2016-17
6 · The paper itself

Abstract

Myricitrin, a naturally occurring flavonoid in Madhuca longifolia, possesses several medicinal properties. Even though our earlier work revealed its role against the proliferation of acute myelogenous leukemia cells (HL-60), its molecular mechanisms have not yet been revealed. The current study aims to explore the molecular mechanisms of myricitrin (isolated from an ethnomedicinal drug Madhuca longifolia) to induce apoptosis in HL-60 cells. Treatment with IC-50 dose of myricitrin (353 µM) caused cellular shrinkage and cell wall damage in HL-60 cells compared to untreated control cells. Myricitrin treatment reduced the mitochondrial membrane potential (22.95%), increased DNA fragmentation (90.4%), inhibited the cell survival proteins (RAS, B-RAF, & BCL-2) and also induced pro-apoptotic proteins (p38, pro-caspase-3, pro-caspase-9 and caspase-3) in the HL-60 cells. The present study provides scientific evidence for the apoptosis caused by myricitrin in HL-60 leukemia cells. Hence, the phytochemical myricitrin could be considered as a potential candidate to develop an anticancer drug after checking its efficacy through suitable pre-clinical and clinical studies.

Indexed as

Apoptosisbcl-2-Associated X ProteinCaspase 3Caspase 9Cell SurvivalDNA FragmentationFlavonoidsHL-60 CellsHumansLeukemiaMadhucaMembrane Potential, MitochondrialMitochondriaPlant ExtractsPlant LeavesProto-Oncogene Proteins c-bcl-2BAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanCASP3 protein, humanCaspase 3Caspase 9FlavonoidsmyricitrinPlant ExtractsProto-Oncogene Proteins c-bcl-2Reactive Oxygen SpeciesApoptosisCell signaling proteinsDNA fragmentationLeukemia cellsMitochondrial membrane potentialMyricitrin

Identifiers

PMID34156605
OpenAlexW3170386080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.